Email Updates

You are here

AVAC in the News

  • Standardized metrics and data collection aid meaningful comparisons of optimal community engagement methods for trial enrollment. Internet strategies had better success in the Americas/Switzerland than in sub-Saharan African countries. Data are essential in outreach staff efforts to improve screening-to-enrollment ratios.

    September 17, 2020
    General
    PLOS One
  • One of South Africa’s three COVID-19 vaccine trials was recently put on hold after a participant in the United Kingdom developed an unexplained illness. After an independent review, AstraZeneca’s candidate, which was considered to be a frontrunner in the field, is expected to resume locally this week. But results are still a long shot for this year, says the trial’s lead investigator.

    September 15, 2020
    General
    Bhekisisa
  • The California law allowing pharmacists to prescribe HIV prevention medication has encouraged lawmakers around the country to pass similar measures to reduce hurdles and expand access to pre-exposure prophylaxis (PrEP). With the passage of Senate Bill 159, California became the first state in the nation to allow pharmacists to provide PrEP and post-exposure prophylaxis (PEP).

    September 10, 2020
    The BodyPro
  • Maureen Luba is the Africa Region Advocacy Advisor at AIDS Vaccine Advocacy Coalition (AVAC) where she helps lead capacity building efforts around strategy development, data analytics and use for advocacy for Civil Society Organizations in Zimbabwe, Tanzania and Malawi to effectively engage in Global Fund, PEPFAR and national policy decision-making processes. She graduated from the University of Malawi with a Bachelor’s Degree in Public Administration.

    September 10, 2020
    General
    BMJ Leader
  • An excellent webinar from AVAC on deleopments in COVID-19 vaccine research is now online featuring a talk by Barney Graham, Director of US NIH Vaccine Research Centre (VRC). The talk reviews the rapid development timeline for COVID-19 vaccines, including the role played by HIV researchers and trial networks, and covers some of the recent research developments.

    August 27, 2020
    General
    i-base
  • On July 24, the European Medicines Agency (EMA) adopted a positive opinion on the dapivirine vaginal ring for use by cisgender women ages 18 and older in developing countries to reduce the risk of HIV. The ring is an important user-controlled option for women who choose not to, or are unable to, use pre-exposure prophylaxis (PrEP).

    August 18, 2020
    The BodyPro
  • Typically, it can take at least a decade to develop a new vaccine, with the shortest timeline in history being four years to develop one for mumps. As part of this process, potential vaccines go through stages of research, from preclinical work in animals to phase one clinical trials that test the safety of potential vaccines in healthy volunteers. From there, vaccine candidates move onto larger phase two and three studies that see if the vaccines are effective at preventing a given disease.

    August 5, 2020
    General
    Bhekisisa
  • Five years into tracking global pre-exposure prophylaxis (PrEP) data, the HIV advocacy organization AVAC has launched a new interactive site that allows users to visualize worldwide country-level information about PrEP use.

    August 5, 2020
    POZ
  • The US government has stepped up efforts to persuade members of minority communities to participate in clinical trials for COVID-19 vaccines, fearing that their historical suspicion of public health authorities will limit the number of volunteers.

    August 4, 2020
    General
    Financial Times
  • As the world waits with baited breath for a safe and effective vaccine to prevent SARS-CoV-2, the new coronavirus that causes COVID-19, people living with HIV are concerned that they may be excluded from clinical trials testing these vaccines.

    July 30, 2020
    General
    POZ

Pages